nach oben

Erschienen in:

19.10.2022 | COVID-19 | Hospital-Based Dermatology (L Guggina and C Nguyen, Section Editors)

SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist

verfasst von: Sonia Himed, Ashley Gray, Zaynah Awethe, Karissa Libson, Benjamin H. Kaffenberger, Abraham M. Korman, John C. L. Trinidad

Erschienen in: Current Dermatology Reports | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The overall purpose of this review was to characterize and summarize cutaneous eruptions associated with coronavirus disease 2019 (COVID-19) as well as COVID-19 vaccination.

Recent Findings

Cutaneous eruptions associated with COVID-19 infection have a reported frequency of 1–20%. Increased COVID-19 disease severity has been associated with morbilliform exanthems, urticaria, retiform purpura, and livedo racemosa. Papulovesicular eruptions were associated with a milder COVID-19 disease course. A range of dermatoses have also been reported with COVID-19 vaccination but have rarely prevented subsequent vaccination.

Summary

Dermatologists should be aware of the associations between COVID-19 disease severity and cutaneous eruptions. Livedo racemosa and retiform purpura are particularly associated with increased disease severity and death. In the setting of COVID-19 vaccination, cutaneous eruptions can largely be managed symptomatically and very rarely do these reactions prevent subsequent vaccination.

World Health Organization. WHO coronovirus (COVID-19) dashboard. 2022.

Jamshidi P, Hajikhani B, Mirsaeidi M, Vahidnezhad H, Dadashi M, Nasiri MJ. Skin manifestations in COVID-19 patients: are they indicators for disease severity? A Systematic Review. Front Med. 2021;16(8): 634208.CrossRef

Recalcati S. Cutaneous manifestations in COVID‐19: a first perspective. J Eur Acad Dermatol Venereol. 2020 May [cited 2022 Jun 13];34(5). Available from: https://doi.org/10.1111/jdv.16387.

•• Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR, et al. The spectrum of COVID-19–associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83(4):1118–29. A current review article characterizing cutaneous manifestations of COVID-19, including prevalence and incidence, as well as their associations with disease severity from over 700 patients globally.

Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.CrossRef

González González F, Cortés Correa C, Peñaranda CE. Manifestaciones cutáneas en pacientes con COVID-19: características clínicas y mecanismos fisiopatológicos postulados. Actas Dermosifiliogr. 2021;112(4):314–23.CrossRef

Selda‐Enriquez G, Fernandez‐Nieto D, Burgos‐Blasco P, Melian‐Olivera A, Fernandez‐Guarino M. Skin manifestations overlap in COVID‐19 patients: a continuous spectrum? Dermatol Ther. 2021 Jan [cited 2022 Jun 13];34(1). Available from: https://doi.org/10.1111/dth.14592.

Bitar C, Chan MP, Harms PW, Fullen DR, Gudjonsson JE, Eshaq M, et al. Cutaneous manifestations of hospitalized coronavirus disease 2019 patients: a report of six cases with clinicopathologic features and viral RNA in situ hybridization. J Eur Acad Dermatol Venereol. 2020 Nov [cited 2022 Jun 13];34(11). Available from: https://doi.org/10.1111/jdv.16741.

•• Askin O, Altunkalem RN, Altinisik DD, Uzuncakmak TK, Tursen U, Kutlubay Z. Cutaneous manifestations in hospitalized patients diagnosed as COVID‐19. Dermatol Ther. 2020 Nov [cited 2022 Jun 13];33(6). Available from: https://doi.org/10.1111/dth.13896. A review article on the cutaneous diseases that were present among 200 patients hospitalized with COVID-19. This study focuses on increased COVID-19 disease severity and characterizes findings associated with critical care patients.

10.

•• Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71–7. A prospective study of COVID-19 associated cutaneous eruptions in 375 patients that are characterized based on morphology. These eruptions were then further associated by disease latency and associations with COVID-19 severity and prognosis.CrossRef

11.

Genovese G, Moltrasio C, Berti E, Marzano AV. Skin manifestations associated with COVID-19: current knowledge and future perspectives. Dermatology. 2021;237(1):1–12.CrossRef

12.

Ahouach B, Harent S, Ullmer A, Martres P, Bégon E, Blum L, et al. Cutaneous lesions in a patient with COVID‐19: are they related? Br J Dermatol. 2020 Aug [cited 2022 Jun 13];183(2). Available from: https://doi.org/10.1111/bjd.19168.

13.

Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID‐19 infection. J Eur Acad Dermatol Venereol. 2020 Jul [cited 2022 Jun 13];34(7). Available from: https://doi.org/10.1111/jdv.16523.

14.

Algaadi SA. Urticaria and COVID ‐19: a review. Dermatol Ther [Internet]. 2020 Nov [cited 2022 Jun 13];33(6). Available from: https://doi.org/10.1111/dth.14290.

15.

Hassan K. Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep. 2020;13(7): e236981.CrossRef

16.

Pagali S, Parikh RS. Severe urticarial rash as the initial symptom of COVID-19 infection. BMJ Case Rep. 2021;14(3): e241793.CrossRef

17.

• Novak N, Peng W, Naegeli MC, Galvan C, Kolm-Djamei I, Brüggen C, et al. SARS-CoV-2, COVID-19, skin and immunology—what do we know so far? Allergy. 2021;76(3):698–713. A recent article that summarizes the current knowledge of associations between COVID-19 and the skin. This report details possible immunologic and vascular mechanisms of different eruptions.

18.

de Perosanz-Lobo D, Fernandez-Nieto D, Burgos-Blasco P, Selda-Enriquez G, Carretero I, Moreno C, et al. Urticarial vasculitis in COVID-19 infection: a vasculopathy-related symptom? J Eur Acad Dermatol Venereol. 2020;34(10):e566–8.

19.

• Marzano AV, Genovese G, Fabbrocini G, Pigatto P, Monfrecola G, Piraccini BM, et al. Varicella-like exanthem as a specific COVID-19–associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. 2020 Jul;83(1):280–5. This article was one of the first to detail the papulovesicular eruptions in 22 patients associated with COVID-19 that were previously reported sporadically as isolated cases.

20.

Assaf J, Sarkis J, Merhy R, Jabbour R, Zeinaty P, Helou‐Mallat J. Cutaneous maculopapular and vesicular lesions as the only presentation of COVID‐19. Int J Dermatol. 2021 Nov [cited 2022 Jun 13];60(11). Available from: https://doi.org/10.1111/ijd.15876.

21.

Barrera-Godínez A, Méndez-Flores S, Gatica-Torres M, Rosales-Sotomayor A, Campos-Jiménez KI, Carrillo-Córdova DM, et al. Not all that glitters is COVID-19: a case series demonstrating the need for histopathology when skin findings accompany SARS-CoV-2 infection. J Eur Acad Dermatol Venereol. 2021;35(9):1865–73.CrossRef

22.

•• Droesch C, Do MH, DeSancho M, Lee EJ, Magro C, Harp J. Livedoid and purpuric skin eruptions associated with coagulopathy in severe COVID-19. JAMA Dermatol. 2020;156(9):1022. This is a case series during the beginning of the COVID-19 outbreak in the USA that detailed four critically ill patients with PCR confirmed COVID-19. These patients all developed livedoid and purpuric skin eruptions that were associated with increased coagulopathy and COVID-19 disease severity. Punch biopsies were also done on all patients which demonstrated vasculopathy.

23.

Khalil S, Hinds BR, Manalo IF, Vargas IM, Mallela S, Jacobs R. Livedo reticularis as a presenting sign of severe acute respiratory syndrome coronavirus 2 infection. JAAD Case Rep. 2020;6(9):871–4.CrossRef

24.

Strom MA, Trager MH, Geskin LJ. Reticular skin eruption as the initial sign of coronavirus disease 2019 infection. JAAD Case Rep. 2020;6(8):790–2.CrossRef

25.

Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020;83(2):700.CrossRef

26.

Tusheva I, Damevska K, Dimitrovska I, Markovska Z, Malinovska-Nikolovska L. Unilateral livedo reticularis in a COVID-19 patient: case with fatal outcome. JAAD Case Rep. 2021;7:120–1.CrossRef

27.

Català A, Galván‐Casas C, Carretero‐Hernández G, Rodríguez‐Jiménez P, Fernández‐Nieto D, Rodríguez‐Villa A, et al. Maculopapular eruptions associated to COVID‐19: a subanalysis of the COVID‐PIEL study. Dermatol Ther. 2020 Nov [cited 2022 Jun 13];33(6). Available from: https://doi.org/10.1111/dth.14170.

28.

Bennardo L, Nisticò SP, Dastoli S, Provenzano E, Napolitano M, Silvestri M, et al. Erythema multiforme and COVID-19: what do we know? Medicina (Mex). 2021;57(8):828.CrossRef

29.

Do MH, Stewart CR, Harp J. Cutaneous manifestations of COVID-19 in the inpatient setting. Dermatol Clin. 2021;39(4):521–32.CrossRef

30.

Jimenez‐Cauhe J, Ortega‐Quijano D, Carretero‐Barrio I, Suarez‐Valle A, Saceda‐Corralo D, Moreno‐Garcia del Real C, et al. Erythema multiforme‐like eruption in patients with COVID‐19 infection: clinical and histological findings. Clin Exp Dermatol. 2020 Oct;45(7):892–5.

31.

Gargiulo L, Pavia G, Facheris P, Valenti M, Sacrini F, Narcisi A, et al. A fatal case of COVID‐19 infection presenting with an erythema multiforme‐like eruption and fever. Dermatol Ther. 2020 Jul [cited 2022 Jun 13];33(4). Available from: https://doi.org/10.1111/dth.13779.

32.

Sanchez A, Sohier P, Benghanem S, L’Honneur AS, Rozenberg F, Dupin N, et al. Digitate papulosquamous eruption associated with severe acute respiratory syndrome coronavirus 2 infection. JAMA Dermatol. 2020;156(7):819.CrossRef

33.

Behrangi E, Sadeghzadeh-Bazargan A, Salimi N, Shaka Z, Feyz Kazemi MH, Goodarzi A. Erythrodermic flare-up of psoriasis with COVID-19 infection: a report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID-19 on each other along with the special challenges of the pandemic. Clin Case Rep. 2022;10(4): e05722.CrossRef

34.

Nuno-Gonzalez A, Martin-Carrillo P, Magaletsky K, Martin Rios MD, Herranz Mañas C, Artigas Almazan J, et al. Prevalence of mucocutaneous manifestations in 666 patients with COVID-19 in a field hospital in Spain: oral and palmoplantar findings. Br J Dermatol. 2021;184(1):184–5.CrossRef

35.

Holcomb ZE, Hussain S, Huang JT, Delano S. Reactive infectious mucocutaneous eruption associated with SARS-CoV-2 infection. JAMA Dermatol. 2021;157(5):603.CrossRef

36.

Bapst T, Romano F, Müller M, Rohr M. Special dermatological presentation of paediatric multisystem inflammatory syndrome related to COVID-19: erythema multiforme. BMJ Case Rep. 2020;13(6): e236986.CrossRef

37.

Torrelo A, Andina D, Santonja C, Noguera-Morel L, Bascuas-Arribas M, Gaitero-Tristán J, et al. Erythema multiforme-like lesions in children and COVID-19. Pediatr Dermatol. 2020;37(3):442–6.CrossRef

38.

Young TK, Shaw KS, Shah JK, Noor A, Alperin RA, Ratner AJ, et al. Mucocutaneous manifestations of multisystem inflammatory syndrome in children during the COVID-19 pandemic. JAMA Dermatol. 2021;157(2):207.CrossRef

39.

Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol. 2020;82(5): e177.CrossRef

40.

Diaz-Guimaraens B, Dominguez-Santas M, Suarez-Valle A, Pindado-Ortega C, Selda-Enriquez G, Bea-Ardebol S, et al. Petechial skin rash associated with severe acute respiratory syndrome coronavirus 2 infection. JAMA Dermatol. 2020;156(7):820.CrossRef

41.

Bomhof G, Mutsaers PGNJ, Leebeek FWG, Boekhorst PAW, Hofland J, Croles FN, et al. COVID‐19‐associated immune thrombocytopenia. Br J Haematol. 2020 Jul [cited 2022 Jun 13];190(2). Available from: https://doi.org/10.1111/bjh.16850.

42.

Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andrès E. Immune thrombocytopenic purpura in a patient with Covid-19. N Engl J Med. 2020;382(18): e43.CrossRef

43.

Pile H, Harp T, Altman D. Atypical erythema nodosum triggered by COVID-19 infection. JAAD Case Rep. 2021;14:91–3.CrossRef

44.

Sipfle DON, Bridwell MDRE, Roper DOJ. Erythema nodosum-like rash in a COVID-19 patient: a case report. Am J Emerg Med. 2021;40:227.e1-227.e2.CrossRef

45.

Suter P, Mooser B, Pham Huu Thien HP. Erythema nodosum as a cutaneous manifestation of COVID-19 infection. BMJ Case Rep. 2020 Jul;13(7):e236613.

46.

Ordieres‐Ortega L, Toledo‐Samaniego N, Parra‐Virto A, Fernández‐Carracedo E, Lavilla‐Olleros C, Demelo‐Rodríguez P. Atypical erythema nodosum in a patient with COVID‐19 pneumonia. Dermatol Ther. 2020 Jul [cited 2022 Jun 13];33(4). Available from: https://doi.org/10.1111/dth.13658.

47.

Agharbi FZ, Oqbani K, Allaoui A, Chikhaoui I, Chiheb S. Sweet syndrome in post-COVID-19 infection: a case report. Travel Med Infect Dis. 2021;44: 102188.CrossRef

48.

Taşkın B, Vural S, Altuğ E, Demirkesen C, Kocatürk E, Çelebi İ, et al. Coronavirus 19 presenting with atypical Sweet’s syndrome. J Eur Acad Dermatol Venereol. 2020 Oct [cited 2022 Jun 13];34(10). Available from: https://doi.org/10.1111/jdv.16662.

49.

Berro S, Calas A, Sohier P, Darbord D, Dupin N. Sweet’s syndrome three weeks after a severe COVID-19 infection: a case report. Acta Derm Venereol. 2021;101(6):adv00486.

50.

Perry T, Rosen H, Pettit C, Trinidad JC. Pressure‐induced alopecia due to proning in COVID‐19. Dermatol Ther. 2021 Mar [cited 2022 Jun 13];34(2). Available from: https://doi.org/10.1111/dth.14764.

51.

Aryanian Z, Balighi K, Hatami P, Afshar ZM, Mohandesi NA. The role of SARS‐CoV‐2 infection and its vaccines in various types of hair loss. Dermatol Ther. 2022 Jun [cited 2022 Jun 13];35(6). Available from: https://doi.org/10.1111/dth.15433.

52.

Herman A, Peeters C, Verroken A, Tromme I, Tennstedt D, Marot L, et al. Evaluation of Chilblains as a manifestation of the COVID-19 pandemic. JAMA Dermatol. 2020;156(9):998.CrossRef

53.

Gambichler T, Boms S, Susok L, Dickel H, Finis C, Abu Rached N, et al. Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol. 2022;36(2):172–80.CrossRef

54.

•• McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46–55. A provider-facing–registry-based study collected 414 cases of cutaneous reactions after COVID-19 vaccination in healthcare workers from December 2020 to February 2021. They recorded information on mRNA vaccines, Moderna (83%) and Pfizer (17%). Only 43% of patients that experienced a first-dose reaction also experienced a reaction with subsequent doses, and no severe adverse events occurred. The study noted delayed large local reactions to be the most common, followed by local injection site reactions, urticarial eruptions, and morbilliform eruptions.

55.

Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Cutaneous adverse reactions associated with SARS-CoV-2 vaccines. J Clin Med. 2021;10(22):5344.CrossRef

56.

Sun Q, Fathy R, McMahon DE, Freeman EE. COVID-19 Vaccines and the skin. Dermatol Clin. 2021;39(4):653–73.CrossRef

57.

Sprute R, Schumacher S, Pauls M, Pauls W, Cornely OA. Delayed cutaneous hypersensitivity reaction to Vaxzevria (ChAdOx1-S) vaccine against SARS-CoV-2. Drugs RD. 2021;21(4):371–4.CrossRef

58.

•• McMahon DE, Kovarik CL, Damsky W, Rosenbach M, Lipoff JB, Tyagi A, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study. J Am Acad Dermatol. 2022;86(1):113–21. The registry-based study utilized 58 complete biopsy reports to characterize histopathologic features and correlate with clinical findings from December 2020 to February 2021. Vaccines manufacturers in the registry included Moderna 46%, Pfizer, Johnson and Johnson, Oxford/AstraZenaca, and unspecified. A total of 13 distinct reaction patterns were identified, and the most common reaction spectrum was identified as vaccine-related eruption of papules and plaques (V-REPP). Biopsy results do not necessarily align with morphologies due to decreased frequency of biopsies for more common reactions. Additionally, only 58 (7%) complete biopsy reports were available out of 803 cutaneous vaccine reactions in the registry.

59.

Mohta A, Sharma MK. Development of delayed dermal hypersensitivity reaction following the second dose of COVID‐19 vaccine—a series of 37 cases. J Eur Acad Dermatol Venereol. 2022 May 18;jdv.18206.

60.

Bianchi L, Biondi F, Hansel K, Murgia N, Tramontana M, Stingeni L. Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: limits of intradermal testing. Allergy. 2021;76(8):2605–7.CrossRef

61.

Robinson LB, Fu X, Hashimoto D, Wickner P, Shenoy ES, Landman AB, et al. Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines. JAMA Dermatol. 2021;157(8):1000.CrossRef

62.

Centers for Disease Control and Prevention. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. Available from: https://www-cdc-gov.proxy.lib.ohio-state.edu/vaccines/covid-19/info-by-product/clinical-considerations.html.

63.

Kim MA, Lee YW, Kim SR, Kim JH, Min T ki, Park HS, et al. COVID-19 Vaccine-associated anaphylaxis and allergic reactions: consensus statements of the KAAACI urticaria/angioedema/anaphylaxis working group. Allergy Asthma Immunol Res. 2021;13(4):526.

64.

Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al. COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14(2): 100517.CrossRef

65.

COVID-19: the green book, Chapter 14a. In UK Health Security COmpany; Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1057798/Greenbook-chapter-14a-28Feb22.pdf.

66.

Alpalhão M, Maia-Silva J, Filipe P. Severe acute respiratory syndrome coronavirus 2 vaccines and cutaneous adverse reactions: a review. Dermatitis. 2021;32(3):133–9.CrossRef

67.

Akinosoglou K, Tzivaki I, Marangos M. Covid-19 vaccine and autoimmunity: awakening the sleeping dragon. Clin Immunol. 2021;226: 108721.CrossRef

68.

Cohen SR, Prussick L, Kahn JS, Gao DX, Radfar A, Rosmarin D. Leukocytoclastic vasculitis flare following the COVID-19 vaccine. Int J Dermatol. 2021;60(8):1032–3.CrossRef

69.

Fiorillo G, Pancetti S, Cortese A, Toso F, Manara S, Costanzo A, et al. Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) after COVID-19 vaccination. J Autoimmun. 2022;127: 102783.CrossRef

70.

Annabi E, Dupin N, Sohier P, Garel B, Franck N, Aractingi S, et al. Rare cutaneous adverse effects of COVID‐19 vaccines: a case series and review of the literature. J Eur Acad Dermatol Venereol. 2021 Dec [cited 2022 Jun 13];35(12). Available from: https://doi.org/10.1111/jdv.17578.

71.

Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol. 2021;93(4):1850–1.CrossRef

72.

Özdemir AK, Kayhan S, Çakmak SK. Herpes zoster after inactivated SARS‐CoV‐2 vaccine in two healthy young adults. J Eur Acad Dermatol Venereol. 2021 Dec [cited 2022 Jun 13];35(12). Available from: https://doi.org/10.1111/jdv.17577.

73.

Niebel D, Ralser‐Isselstein V, Jaschke K, Braegelmann C, Bieber T, Wenzel J. Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine. Dermatol Ther. 2021 Jul [cited 2022 Jun 13];34(4). Available from: https://doi.org/10.1111/dth.15017.

74.

Coto-Segura P, Fernández-Prada M, Mir-Bonafé M, García-García B, González-Iglesias I, Alonso-Penanes P, et al. Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature. Clin Exp Dermatol. 2022;47(1):141–3.CrossRef

75.

Lospinoso K, Nichols CS, Malachowski SJ, Mochel MC, Nutan F. A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine. JAAD Case Rep. 2021 Jul;13:134–7.

76.

Dash S, Sirka CS, Mishra S, Viswan P. COVID-19 vaccine-induced Stevens-Johnson syndrome. Clin Exp Dermatol. 2021;46(8):1615–7.CrossRef

77.

Kong J, Cuevas-Castillo F, Nassar M, Lei CM, Idrees Z, Fix WC, et al. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: case report. J Infect Public Health. 2021;14(10):1392–4.CrossRef

78.

Juay L, Chandran NS. Three cases of vesiculobullous non‐IgE‐mediated cutaneous reactions to tozinameran (Pfizer‐BioNTech COVID‐19 vaccine). J Eur Acad Dermatol Venereol. 2021 Dec [cited 2022 Jun 14];35(12). Available from: https://doi.org/10.1111/jdv.17581.

79.

Lopatynsky-Reyes EZ, Acosta-Lazo H, Ulloa-Gutierrez R, Ávila-Aguero ML, Chacon-Cruz E. BCG scar local skin inflammation as a novel reaction following mRNA COVID-19 vaccines in Two International Healthcare Workers. Cureus. 2021 Apr 13 [cited 2022 Jun 13]; Available from: https://www.cureus.com/articles/55547-bcg-scar-local-skin-inflammation-as-a-novel-reaction-following-mrna-covid-19-vaccines-in-two-international-healthcare-workers.

80.

Munavalli GG, Guthridge R, Knutsen-Larson S, Brodsky A, Matthew E, Landau M. COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment. Arch Dermatol Res. 2022;314(1):1–15.CrossRef

81.

Stewart R, McDowell L. Radiation recall phenomenon following COVID-19 vaccination. Int J Radiat Oncol. 2021;111(3):835–6.CrossRef

82.

Soyfer V, Gutfeld O, Shamai S, Schlocker A, Merimsky O. COVID-19 Vaccine-induced radiation recall phenomenon. Int J Radiat Oncol. 2021;110(4):957–61.CrossRef

83.

Torrealba-Acosta G, Martin JC, Huttenbach Y, Garcia CR, Sohail MR, Agarwal SK, et al. Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine. BMJ Case Rep. 2021;14(7): e243173.CrossRef

84.

Ring J, Worm M, Wollenberg A, Thyssen JP, Jakob T, Klimek L, et al. Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases—practical recommendations. A position statement of ETFAD with external experts. J Eur Acad Dermatol Venereol. 2021 Jun [cited 2022 Jun 13];35(6). Available from: https://doi.org/10.1111/jdv.17237.

85.

van Dam CS, Lede I, Schaar J, Al-Dulaimy M, Rösken R, Smits M. Herpes zoster after COVID vaccination. Int J Infect Dis. 2021;111:169–71.CrossRef

86.

Fathy RA, McMahon DE, Lee C, Chamberlin GC, Rosenbach M, Lipoff JB, et al. Varicella zoster and herpes simplex virus reactivation post‐COVID‐19 vaccination: a review of 40 cases in an International Dermatology Registry. J Eur Acad Dermatol Venereol. 2022 Jan [cited 2022 Jun 20];36(1). Available from: https://doi.org/10.1111/jdv.17646.

Titel: SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist
verfasst von: Sonia Himed
Ashley Gray
Zaynah Awethe
Karissa Libson
Benjamin H. Kaffenberger
Abraham M. Korman
John C. L. Trinidad
Publikationsdatum: 19.10.2022
Verlag: Springer US
Schlagwort: COVID-19
Erschienen in: Current Dermatology Reports / Ausgabe 4/2022
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-022-00374-5

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist